Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2016
No. of pages: 658
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals

Biomarker partnering agreement structure

Biomarker partnering contract documents

Top biomarker deals by value

Most active biomarker dealmakers

The Global Biomarker Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 1,000 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Biomarker partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biomarker dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biomarker deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biomarker dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biomarker dealmaking with a brief summary followed by a comprehensive listing of Biomarker deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Biomarker partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biomarker technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Biomarker partnering company A-Z, deal type definitions and Biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Biomarker partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biomarker technologies and products.

Key benefits

Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of biomarker deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of biomarker agreements with numerous real life case studies

Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies

Access to most active biomarker dealmakers since 2010

Insight into the terms included in a biomarker agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

Trends in biomarker dealmaking in the biopharma industry since 2010

Analysis of biomarker deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life biomarker deals

Access to biomarker contract documents

The leading biomarker deals by value since 2010

Most active biomarker dealmakers since 2010

The leading biomarker partnering resources

In Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,000 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biomarker dealmaking
2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Most active Biomarker dealmakers
2.4. Biomarker partnering by deal type
2.5. Biomarker partnering by therapy area
2.6. Deal terms for Biomarker partnering
2.6.1 Biomarker partnering headline values
2.6.2 Biomarker deal upfront payments
2.6.3 Biomarker deal milestone payments
2.6.4 Biomarker royalty rates

Chapter 3 - Leading Biomarker deals
3.1. Introduction
3.2. Top Biomarker deals by value

Chapter 4 - Most active Biomarker dealmakers
4.1. Introduction
4.2. Most active Biomarker dealmakers
4.3. Most active Biomarker partnering company profiles

Chapter 5 - Biomarker contracts dealmaking directory
5.1. Introduction
5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Biomarker deals by company A-Z
Appendix 2 - Biomarker deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Biomarker deals by deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Biomarker deals by therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Pediatrics
Psychiatry
Respiratory
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Biomarker partnering since 2010
Figure 2: Active Biomarker dealmaking activity- 2010 to 2016
Figure 3: Biomarker partnering by deal type since 2010
Figure 4: Biomarker partnering by disease type since 2010
Figure 5: Biomarker deals with a headline value
Figure 6: Biomarker deals with an upfront value
Figure 7: Biomarker deals with a milestone value
Figure 8: Biomarker deals with a royalty rate value
Figure 9: Top Biomarker deals by value since 2010
Figure 10: Most active Biomarker dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Europe Cancer Biomarkers Market Report 2016
    Published: 25-Oct-2016        Price: US 3900 Onwards        Pages: 124
    Notes: Sales, means the sales volume of Cancer Biomarkers Revenue, means the sales value of Cancer Biomarkers This report studies sales (consumption) of Cancer Biomarkers in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Abbott Laboratories (U.S.) - Affymetrix Inc. (U.S.) - Roch......
  • United States Cancer Biomarkers Market Report 2016
    Published: 25-Oct-2016        Price: US 3800 Onwards        Pages: 120
    Notes: Sales, means the sales volume of Cancer Biomarkers Revenue, means the sales value of Cancer Biomarkers This report studies sales (consumption) of Cancer Biomarkers in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Abbott Laboratories (U.S.) - Affymetrix Inc. (U.S.) - Roche Diagnostics Ltd. (Switzerland) - Illumina, Inc. (U.S.) - Qiagen NV (Netherlands)......
  • China Cancer Biomarkers Market Research Report 2016
    Published: 25-Oct-2016        Price: US 3200 Onwards        Pages: 116
    Notes: Sales, means the sales volume of Cancer Biomarkers Revenue, means the sales value of Cancer Biomarkers This report studies Cancer Biomarkers in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Abbott Laboratories (U.S.) - Affymetrix Inc. (U.S.) - Roche Diagnostics Ltd. (Switzerland) - Illumina, Inc. (U.S.) - Qiagen NV (Nether......
  • Global Cancer Biomarkers Market Research Report 2016
    Published: 24-Oct-2016        Price: US 2900 Onwards        Pages: 106
    Notes: Production, means the output of Cancer Biomarkers Revenue, means the sales value of Cancer Biomarkers This report studies Cancer Biomarkers in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Abbott Laboratories (U.S.) - Affymetrix Inc. (U.S.) - Roche Diagnostics Ltd. (......
  • Global Neurological Biomarkers Market 2016-2020
    Published: 08-Sep-2016        Price: US 2500 Onwards        Pages: 68
    Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers. The analysts forecast global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020. Cover......
  • Global Circulating Biomarker Sales Market Report 2021
    Published: 12-Aug-2016        Price: US 4000 Onwards        Pages: 129
    This report studies sales (consumption) of Circulating Biomarker in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - BIOCEPT, INC. - QIAGEN - HOFFMANN-LA ROCHE AG - BIO-RAD LABORATORIES INC. - MYRIAD GENETICS - JANSSEN DIAGNOSTICS, LLC. - TR0VAGENE INC. - GUARD......
  • United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 Market Research Report
    Published: 11-Aug-2016        Price: US 3800 Onwards        Pages: 130
    The United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Commercializing Biomarkers in Therapeutic and Diagnostic Applications marke......
  • Global Cardiac Markers Sales Market Report 2021
    Published: 09-Aug-2016        Price: US 4000 Onwards        Pages: 126
    This report studies sales (consumption) of Cardiac Markers in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.) - ABBOTT LABORATORIES, INC. - SIEMENS AG - ALERE INC. - JOHNSON & JOHNSON - INSTRUMENTATION LA......
  • United States Circulating Biomarker Sales Market Report 2021
    Published: 03-Aug-2016        Price: US 3800 Onwards        Pages: 124
    This report studies sales (consumption) of Circulating Biomarker in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering BIOCEPT, INC. QIAGEN HOFFMANN-LA ROCHE AG BIO-RAD LABORATORIES INC. MYRIAD GENETICS JANSSEN DIAGNOSTICS, LLC. TR0VAGENE INC. GUARDANT HEALTH INC. FRAUNHOFER-GESELLSCHAFT MDX HEALTH SA Split by prod......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs